Objective To determine whether autologous infusions of expanded regulatory T lymphoctyes (Tregs) into patients with amyotrophic lateral sclerosis (ALS) are safe and tolerable during early and later stages of disease.
Abstract
Objective To determine whether autologous infusions of expanded regulatory T lymphoctyes (Tregs) into patients with amyotrophic lateral sclerosis (ALS) are safe and tolerable during early and later stages of disease.
Methods
Three patients with ALS, with no family history of ALS, were selected based on their differing sites of disease onset and rates of progression. Patients underwent leukapheresis, and Tregs were subsequently isolated and expanded ex vivo. Tregs (1 × 10 6 cells/kg) were administered IV at early stages (4 doses over 2 months) and later stages (4 doses over 4 months) of disease. Concomitant interleukin-2 (2 × 10 5 IU/m 2 /injection) was administered subcutaneously 3 times weekly over the entire study period. Patients were closely monitored for adverse effects and changes in disease progression rates. Treg numbers and suppressive function were assayed during and following each round of Treg infusions.
Results
Infusions of Tregs were safe and well tolerated in all patients. Treg numbers and suppressive function increased after each infusion. The infusions slowed progression rates during early and later stages of disease. Spearman correlation analyses showed that increased Treg suppressive function correlated with slowing of disease progression per the Appel ALS scale for each patient: patient 1: ρ (rho) = −0.60, p = 0.003; patient 2: ρ = −0.71, p = 0.0026; and patient 3: ρ = −0.54, p = 0.016. Measures of maximal inspiratory pressure also stabilized, particularly in 2 patients, during Treg infusions.
Conclusions
These results demonstrate the safety and potential benefit of expanded autologous Treg infusions, warranting further clinical trials in patients with ALS. The correlation between Treg suppressive function and disease progression underscores the significance of using Treg suppressive function as an indicator of clinical status.
Classification of evidence
This study provides Class IV evidence. This is a phase I trial with no controls.
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Class of Evidence
Criteria for rating therapeutic and diagnostic studies NPub.org/coe CD4 + CD25 + FOXP3 + regulatory T lymphocytes (Tregs) are a subpopulation of T lymphocytes that are immunosuppressive and maintain tolerance to self-antigens, with their dysfunction playing a pivotal role in the development of autoimmune disorders. [1] [2] [3] [4] In amyotrophic lateral sclerosis (ALS) mice, infusions of Tregs slow disease progression and prolong survival, and Tregs suppress the proliferation of responder T lymphocytes and the activation of microglia. 5, 6 In patients with ALS, the expression of the Treg master transcription factor FOXP3 is reduced in rapidly progressing patients, 7 with subsequent impairment of Treg suppressive functions; FOXP3 expression and Treg suppressive functions correlate with the extent and rapidity of disease progression. 8 When expanded ex vivo in the presence of interleukin (IL)-2 and rapamycin, Treg suppressive function is restored. 8, 9 These data suggest that infusions of expanded autologous Tregs will improve Treg suppressive function in vivo and slow rates of disease progression in patients with ALS. To test these hypotheses, a first-in-human phase 1 study was initiated to determine whether infusions of expanded autologous Tregs into patients with ALS were safe and tolerable during early and later stages of disease. IL-2 was administered concomitantly in the patients in an effort to stabilize and possibly enhance the suppressive functions of the infused Tregs. Furthermore, the relationship between ex vivo Treg suppressive functions and patients' clinical statuses was explored. 4 IL-2 was administered subcutaneously 3 times weekly at a dose of 2 × 10 5 IU/m 2 /injection beginning the day after the first Treg infusion and continued throughout the study period.
Methods
Primary research question
Infusions of expanded autologous Tregs
Leukapheresis was performed 1 month before the first Treg infusion. Tregs were isolated and expanded ex vivo in the Good Manufacturing Practice-compliant facility at M.D. Anderson Cancer Center according to a previously described protocol. 8, 9 Each Treg infusion was administered IV through a peripheral line, and patients were closely monitored for any infusion-related adverse responses for 4 hours after the infusion.
Clinical evaluations
The revised ALS Functional Rating Scale (ALSFRS-R), Appel ALS Rating Scale (AALS), 10 and maximal inspiratory pressure (MIP) measurements were performed immediately before each Treg infusion, every 2 weeks during each round of infusions, and monthly after each round. Forced vital capacity (FVC) was monitored at each evaluation as a component of the AALS. Patients were asked about adverse events at each encounter.
Assessing Treg percentage and suppressive function in the peripheral blood Peripheral blood was drawn 1 month before the first Treg infusion, immediately before each infusion, the day after each infusion, every 2 weeks during each round of infusions, and monthly after each round. The percentage of CD4
+ Tregs within the total CD4 + population was assessed by flow cytometry. 8 Treg suppressive function on the 
Statistical analysis
Correlation between changes in the AALS and Treg suppressive function was determined by Spearman correlation using GraphPad Prism 7 software and depicted by Spearman rho (ρ). Two-tailed p values <0.05 were considered statistically significant. Data collected between the first and fifth Treg infusions were compared with values from the day of the first infusion. Data collected after the fifth Treg infusion were compared with the values from the day of the fifth infusion.
Data availability
Individual deidentified patient data not published within the article including clinical evaluations and Treg percentage and suppressive function results will be shared by request from any qualified investigator.
Results
Safety
No infusion-related adverse events or clinically significant changes in safety laboratories or electrocardiogram findings were observed. All patients noted dramatic increases in the frequency, intensity, and distribution of fasciculations during each round of infusions. suppressive function, the smaller the decline in the AALS at the next clinical evaluation.
MIPs stabilized during infusions
In all patients, the FVC remained relatively unchanged during the Treg infusions and between each round (figure 3, A-C).
In patients 1 and 3, the MIPs were stable during the first round of infusions and deteriorated between each round. The MIPs again stabilized during the second round. Patient 2 was treated with noninvasive ventilation before enrollment and continued treatment throughout the study. In patient 2, MIPs were low, but remained relatively stable during each round of infusions and between each round (figure 3, D-F).
Discussion
Three patients with ALS were infused with autologous expanded Tregs with concomitant subcutaneous IL-2 injections at early and later stages of disease. Tregs were also infused at a later stage of disease to determine whether the infusions remained safe and the beneficial effects on disease progression could be extended by increasing the dosing interval. Treg infusions were safe and well tolerated regardless of the burden of disease. Treg suppressive function correlated with changes in the AALS; the greater the improvement in Treg suppressive function, the slower the rate of clinical progression. This correlation supports the value of Treg suppressive function as a meaningful indicator of clinical status. In addition, Treg infusions did not adversely affect respiratory function and appeared to stabilize the decline in MIPs in the 2 patients who were not being treated with noninvasive ventilation.
In a previous pilot study, low-dose IL-2 administered subcutaneously for 1 year in 5 patients with ALS was safe and tolerable, but did not appear to alter the clinical course or increase endogenous Treg numbers, likely related to impaired endogenous Treg responsiveness to IL-2 (unpublished results). In the present study, subcutaneous injections of lowdose IL-2 were administered to stabilize the infused expanded Tregs. During infusions in all patients, several data points were observed in which IL-2 could have enhanced the proliferation and function of infused Tregs. However, IL-2 was Common to all patients was the perceived increase in fasciculations. The rapid onset of fasciculations suggests a peripheral action in the lower motor neuron possibly mediated by immune modulation of ectopic axonal firing. In the earlier IL-2-alone pilot study, increased fasciculations were not observed, suggesting that the infused Tregs directly or indirectly caused the fasciculations in this study. In addition, common to all patients was the occurrence of infections during the study: pharyngitis in patient 1, aspiration pneumonia in patient 2, and gastrointestinal and upper respiratory infections in patient 3. A potential increased risk of infections with Treg and IL-2 treatment is concerning and requires further study in a larger number of patients with ALS.
Although this study lacked blinding and placebo controls, slowing of disease progression was observed during the initial infusions at an early stage of disease and the subsequent 4 monthly infusions at a later stage of disease. Administering the ALSFRS-R to the patients during the initial infusions every 2 weeks enhances the likelihood of a placebo effect. However, we have not observed stabilization of the AALS in previous studies of subcutaneous IL-2 injections (unpublished) or infusions of allogeneic hematopoietic stem cells. 11 Furthermore, the increased Treg suppressive function, which correlated with the clinical state, and the observed stabilization of MIPs were not likely to have been influenced by a placebo effect. Increased clinical progression rates were observed between each round of infusions, but it was not clear whether the progression was related to the cessation of Treg infusions or would have occurred spontaneously. More pertinent is the observation that subsequent Treg infusions were beneficial at later stages of disease with increased disease burden and rate of progression. Circulating functional Tregs may slow disease progression by suppressing peripheral proinflammatory monocytes/macrophages and responder T lymphocytes, as well as entering the CNS and suppressing activated microglia. Defining peripheral and central actions of Tregs merits further investigation.
The results from this study support the need for a phase 2, randomized, placebo-controlled trial over a longer period to test the clinical efficacy, safety, and tolerability of different doses of Tregs in a larger number of patients with ALS. The goal of future studies is to determine whether optimized doses of Tregs infused at regular intervals prolong slowed progression and minimize the more rapid progression associated with cessation of Treg infusions.
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